The National Blood Authority (NBA) manages the appropriate use of Immunoglobulin (Ig) in Australia in accordance with the approved indications set out in the Criteria for the clinical use of immunoglobulin in Australia.
This is applicable for both intravenous (IV) and subcutaneous (SC) immunoglobulins.
Online resource - Criteria for the clinical use of immunoglobulin in Australia
The Criteria for immunoglobulin use in Australia is available on the National Blood Authority website.
The National Blood Authority has introduced this supply and governance structure to address the continued growth in demand for IVIg. It aims to ensure equity and sustainability of this resource.
Immunoglobulin safety notice
There is a potential for issuing and administration errors due to the new look-alike, sound-alike IVIg and SCIg products.
Download the safety alert for more information or to distribute to relevant areas.
Intravenous Immunoglobulin (IVIg) - changes to supply and governance
Resources related to changes to the supply of intravenous immunoglobulin.
Subcutaneous immunoglobulin (SCIg)
Information and resources to support the subcutaneous immunoglobulin (SCIg) program, including latest updates.
Updated